Connect Biopharma Slides 8.8% as Market Volatility Hits T‑Cell Therapy Stock
Connect Biopharma’s sharp 8.8% drop reveals hidden volatility and investor caution—discover why its T‑cell therapy pipeline still holds upside potential.
- CONNECT BIOPHARMA HOLDINGS L
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read